News at CenExel

March 24, 2023

Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-3 Trial of KarXT in Schizophrenia

CenExel is proud to announce that the work of David Walling, PhD, CEO and Principal Investigator at CenExel CNS, joined lead author, John H Krystal,...

November 10, 2022

Validation of a suite of ERP and QEEG biomarkers in a pre-competitive, industry-led study in subjects with schizophrenia and healthy volunteers.

Validation of a suite of ERP and QEEG biomarkers in a pre-competitive, industry led-study in subjects with schizophrenia and healthy volunteers.

April 3, 2022

Cultivating Retention in Schizophrenia and Schizoaffective Disorder Studies: Patient Preferences for Clinical Trial Methodologies and COVID19 Mitigations

CenExel is proud to highlight the poster presented at the Schizophrenia International Research Society (SIRS) Annual Scientific Meeting, April 2022, Florence Italy. ABSTRACT Background: Clinical...